HCV: adding RBV to DAAs temporarily reduces QoL

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Real-world patients receiving ribavirin (RBV)-containing direct-acting antiviral (DAA) regimens report a temporary decreased QoL during treatment, confirming observations from phase 2/3 clinical trials.

Why this matters

  • Current data suggest that long-term effects are driven...